Analyzing Opiant Pharmaceuticals (OPNT) and its Competitors

Opiant Pharmaceuticals (NASDAQ: OPNT) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Opiant Pharmaceuticals to similar companies based off the strength of its risk, profitability, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Opiant Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 38.89% 5,686.82% 87.49%
Opiant Pharmaceuticals Competitors -12,670.44% 217.87% -23.42%

Valuation and Earnings

This table compares Opiant Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million $5.99 million 19.49
Opiant Pharmaceuticals Competitors $577.88 million $241.58 million -6.01

Opiant Pharmaceuticals’ competitors have higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently the more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Opiant Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Opiant Pharmaceuticals Competitors 189 901 1674 66 2.57

All “Biopharmaceuticals” companies have a potential upside of 0.31%. Given Opiant Pharmaceuticals’ competitors higher possible upside, analysts plainly believe Opiant Pharmaceuticals has less favorable growth aspects than its competitors.

Risk and Volatility

Opiant Pharmaceuticals has a beta of -0.75, meaning that its share price is 175% less volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals’ competitors have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.

Institutional and Insider Ownership

45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply